Clinical trials: Hypersensitivity, Immediate
Asthma
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus
Pharmacokinetic study comparing Salmeterol/fluticasone Easyhaler products and Seretide Diskus 50/500 µg/inhalation; a randomised, open, single centre, single dose, crossover study in healthy subjects
- Trial name
- NCT03060044
- Testing
- Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus
- Where
- Finland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique
This study was designed to examine the effectiveness of a breath-operated albuterol inhaler in asthma patients who have difficulty using their standard "press-and-breathe" inhaler.
- Trial name
- NCT00054964
- Testing
- Albuterol HFA-BOI, Albuterol HFA-MDI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hereditary Angioedema
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
- Trial name
- NCT05392114
- Testing
- Donidalorsen
- Where
- 50 sites in United States, Belgium and 12 more
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Study is Being Conducted in Healthy Volunteers
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device.
- Trial name
- NCT02934607
- Testing
- Symbicort pMDI with spacer device, Symbicort pMDI without spacer device
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hereditary Angioedema
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
The study objective was to evaluate the safety and efficacy of prophylactic use of C1INH-nf for the prevention of acute HAE attacks.
- Trial name
- CHANGE 3 (NCT00462709)
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 48 sites in United States
- Volunteers
- 146 people
- Sponsor
- Shire
Asthma
European Cost of Asthma Treatment
The economic cost of asthma is considerable both in terms of direct medical costs (such as the cost of pharmaceuticals and hospital admissions) and indirect medical costs (such as time lost from work and premature death).
- Trial name
- EU-COAST (NCT01376219)
- Testing
- asthma control test
- Where
- Spain
- Volunteers
- 2,752 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118792
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Pfizer
Solar Urticaria
Phase II Solar Urticaria (SU) Pilot Study
Urticaria is one of the most common dermatological conditions with diverse clinical presentations and causes. Solar urticaria (SU) is a rare subset of physical urticaria, where symptoms are induced by direct exposure of the skin…
- Trial name
- NCT00859534
- Testing
- afamelanotide
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Clinuvel Pharmaceuticals Limited
Asthma
BI 443651 Methacholine Challenge
The primary objective of this study is to investigate safety and tolerability of three consecutive administrations, 12 hours apart, at three different dose-levels of BI 443651 administered via oral inhalation in male and female…
- Trial name
- NCT03135899
- Testing
- BI 443651
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Rhinitis, Allergic, Perennial
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
- Trial name
- NCT02498509
- Testing
- CKD-342, Mometasone furoate, Levocabastine HCL
- Where
- South Korea
- Volunteers
- 459 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118612
- Testing
- Tree MATA MPL - Therapeutic Regimen, Tree MATA MPL - Intermediate dose, Tree MATA MPL - Low dose
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Cow Milk Allergy
Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula
Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order.
- Trial name
- NCT03236207
- Testing
- Test extensively hydrolyzed formula, Control extensively hydrolyzed formula
- Where
- 12 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Asthma
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
This study was intended to demonstrate that patients with standard and high immunoglobulin E (IgE) levels can be protected from allergen induced broncho-constriction by Xolair
- Trial name
- NCT00624832
- Testing
- Xolair
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis
Asthma
Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence
The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI…
- Trial name
- SiASMARTer (NCT06908421)
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Chiesi Pharma AB, Nordic
Hereditary Angioedema
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.
- Trial name
- NCT01005888
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- Shire
Asthma
Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594
AZD7594 is in clinical development for the treatment of asthma. This is a single centre, open-label, single period study in 6 healthy subjects, to determine the mass balance recovery and generate samples to enable metabolite…
- Trial name
- NCT04002427
- Testing
- Intravenous Infusion, Inhaled dose
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
The primary objective will be to compare the formulations regarding their impact on the pulmonary function of persistent asthma patients and the secondary objective will be the clinical control of the disease's symptoms.
- Trial name
- CAINAS SF (NCT01202097)
- Testing
- Salmeterol/Fluticasone, Seretide
- Where
- 6 sites in Brazil
- Volunteers
- 334 people
- Sponsor
- Eurofarma Laboratorios S.A.
Asthma
Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633
This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.
- Trial name
- NCT01086462
- Testing
- GSK2239633
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
- Trial name
- CONTROL (NCT01225315)
- Testing
- Setipiprant
- Where
- 97 sites in United States, Australia and 11 more
- Volunteers
- 438 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma